Alumis Inc. (ALMS)

Alumis completed an upsized public offering in January 2026, raising approximately $345.1 million, accompanied by insider buying and positive analyst coverage. The company participated in investor conferences in February 2026. In March 2026, Alumis reported positive Phase 3 topline results for envudeucitinib in moderate-to-severe plaque psoriasis, demonstrating significant improvements and plans to submit an NDA in the second half of 2026, with Phase 2b topline data for SLE anticipated in the third quarter of 2026. Alumis stock has rallied 250% in the past year, with its share price increasing by 117.87% from April 7, 2025, to April 6, 2026.

Information regarding specific demand seasonality for Alumis, Inc.'s products and services is not available. As a clinical-stage biopharmaceutical company, its revenue in 2025 was entirely from licensing and collaboration, not product sales, suggesting that product demand seasonality is not yet a significant factor. The demand for its future products will likely be driven by the prevalence of the targeted diseases rather than seasonal patterns.

Alumis, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing targeted medicines for autoimmune and nervous system diseases, replacing broad immunosuppression with precision therapies identified through a proprietary data analytics platform. The company's pipeline includes envudeucitinib, an oral TYK2 inhibitor in late-stage clinical development for systemic immune-mediated disorders; A-005, a CNS-penetrant allosteric TYK2 inhibitor in Phase 1 development for neuroinflammatory and neurodegenerative diseases; lonigutamab, an injectable antibody targeting IGF-1R for thyroid eye disease; and preclinical programs targeting new drug targets for immune system disorders.

Alumis Inc. is headquartered in South San Francisco, California, United States, and has expanded its clinical trials globally to include the US, Europe, Japan, and the Asia-Pacific region since 2024.

Alumis's brand reputation has been positively influenced by clinical advancements and investor confidence, particularly the positive Phase 3 trial results for envudeucitinib in psoriasis, which generated social media buzz and stock interest. Insider buying, a successful public offering, and positive analyst ratings further support this sentiment. The company's data-driven approach and targeted drug development contribute to its reputation as an innovative player.

Alumis Inc. is owned by a mix of institutional shareholders (62.16%), insiders (21.25%), and retail investors (16.59%). Major institutional owners include AyurMaya Capital Management Company, LP, Foresite Capital Management V, LLC, Samsara BioCapital, LLC, venBio Partners LLC, BlackRock, Inc., Vanguard Group Inc, and Matrix Capital Management Company, LP. Srinivas Akkaraju is a significant individual insider owner.